Shots:

• The P-III trial (CAPItello-291) evaluating capivasertib + Faslodex vs PBO + Faslodex in 708 patients with HR+, HER2-low or negative breast cancer, following recurrence or progression on or after endocrine therapy. Capivasertib was discovered by AstraZeneca in collaboration with Astex
• The results showed a PFS improvement. In the overall trial & AKT pathway biomarker-altered population, 40% & 50% reduction in risk of disease progression or death; m-PFS (7.2 vs 3.6mos.) & (7.3 vs 3.1mos.); ORR (22.9% vs 12.2%) & (28.8% vs 9.7%) while OS data were immature with an early encouraging data
• The safety profile was consistent with prior trials. Capivasertib is being studied in P-III trials for multiple subtypes of breast & prostate cancer and a P-II trial for hematologic malignancies

Ref: AstraZeneca | Image: AstraZeneca